CRVO
CervoMed Inc.·Healthcare
3.09
1.311%(+0.04)
Market OpenLast Updated: — ET
52W L: $2.8252W H: $13.13
CRVO NEWS
globenewswire.com
May 18
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing
globenewswire.com
Apr 22
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
globenewswire.com
Apr 7
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
defenseworld.net
Mar 20
Illumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ: ILMN) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,361 shares of the life sciences company's stock after selling 12,818 shares during the period. CIBC
globenewswire.com
Mar 19
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial
defenseworld.net
Mar 19
Head-To-Head Survey: Illumina (NASDAQ:ILMN) versus CervoMed (NASDAQ:CRVO)
Illumina (NASDAQ: ILMN - Get Free Report) and CervoMed (NASDAQ: CRVO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Analyst Ratings This is a summary of current recommendations and
